Metabolon, a provider of metabolomics-driven biomarker discovery and analysis, has announced that it is collaborating with Ralph DeFronzo and colleagues at The University of Texas Health Science Center at San Antonio.
The partnership will help drive development of Metabolon’s pre-diabetes diagnostic products as well as provide valuable data for insulin resistance and diabetes-related research.
Metabolon will be analyzing samples from various studies conducted by Dr DeFronzo’s team to discover and validate biochemical biomarkers reflective of insulin resistance and beta cell dysfunction.
These biomarkers will be used to help further develop Metabolon’s diagnostic tests in the area of insulin resistance, and how this relates to risk of developing metabolic diseases such as diabetes.
John Ryals, CEO of Metabolon, said: “It is through collaborations like this one with Dr DeFronzo’s team that Metabolon will be able to offer a unique diagnostic test that can help physicians to identify asymptomatic, pre-diabetic patients years before they become diabetic.”
Comments